0001193125-23-268942.txt : 20231102 0001193125-23-268942.hdr.sgml : 20231102 20231102091330 ACCESSION NUMBER: 0001193125-23-268942 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231102 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Arcellx, Inc. CENTRAL INDEX KEY: 0001786205 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 472855917 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41259 FILM NUMBER: 231370349 BUSINESS ADDRESS: STREET 1: 25 WEST WATKINS MILL ROAD STREET 2: SUITE A CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-723-6641 MAIL ADDRESS: STREET 1: 25 WEST WATKINS MILL ROAD STREET 2: SUITE A CITY: GAITHERSBURG STATE: MD ZIP: 20878 8-K 1 d572316d8k.htm 8-K 8-K
false 0001786205 0001786205 2023-11-02 2023-11-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 2, 2023

 

 

Arcellx, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Delaware   001-41259   47-2855917
(State or Other Jurisdiction
of Incorporation)
 

(Commission

File Number)

  (IRS Employer
Identification No.)

 

25 West Watkins Mill Road

Suite A

   
Gaithersburg, Maryland     20878
(Address of Principal Executive Offices)     (Zip Code)

Registrant’s Telephone Number, Including Area Code: 240 327-0603

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading
Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ACLX   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

 

 

 


Item 8.01

Other Events.

On November 2, 2023, Arcellx, Inc. (the “Company”) issued a press release announcing the release of an abstract with new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma with data from a June 2, 2023 data cut. The Company announced that it will be presenting on additional clinical data from the Phase 1 study of CART-ddBCMA at its oral presentation at the 65th American Society of Hematology Annual Meeting and Exposition taking place December 9-12, 2023 in San Diego, California. The Company will also host a webcast at 8:00 p.m. PT on December 11, 2023, with an expert panel of clinicians to discuss the Company’s clinical results. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

 No. 

  

Description

99.1    Press Release dated November 2, 2023
104    Cover Page Interactive Data File (embedded within the Inline XBRL Document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      Arcellx, Inc.
Date: November 2, 2023     By:  

/s/ Rami Elghandour

     

Rami Elghandour

Chief Executive Officer

EX-99.1 2 d572316dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Arcellx Announces Oral Presentation for Its CART-ddBCMA Phase 1 Trial in Patients with Relapsed or Refractory Multiple Myeloma at the 65th ASH Annual Meeting and Exposition

— Abstract released today is from a June 2, 2023 data cut —

— Median duration of response, progression free survival, and overall survival rate not reached with median follow-up after CART-ddBCMA infusion of 22 months —

— A more recent data cut will be shared during the oral presentation with a median follow-up of 26.5 months —

— Company to host a live webcast event with an expert panel of clinicians —

REDWOOD CITY, Calif., November 2, 2023 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refractory multiple myeloma will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 9-12, 2023 in San Diego, California. The data in the ASH abstract published today is from a June 2, 2023 data cut. The oral presentation at ASH will be on Monday, December 11, 2023, at 5 p.m. PT and will include new data with a median follow-up of 26.5 months. The company will also have a medical affairs booth (#748) in Hall E of the San Diego Convention Center.

As detailed in the abstract (#1023), 38 patients were evaluable for efficacy and safety analysis as of the June 2, 2023 cutoff date, based on a median follow-up of 22 months following treatment. These evaluable patients comprised the dose escalation cohorts for the first dose level (100 (+/- 20) million CAR+ T cells, n=6) and the second dose level (300 (+/- 20) million CAR+ T cells, n=6), and a dose expansion cohort at 100 (+/- 20) million CAR+ T cells (n=26). The median dose administered to patients in the first dose level and dose expansion cohorts was 115 million CAR+ T cells. All patients evaluable for this analysis have poor prognostic factors with 38 of 38 (100%) patients triple-refractory, 26 of 38 (68%) penta-refractory, and 34 of 38 (89%) refractory to last-line of treatment by International Myeloma Working Group (IMWG) criteria. Additionally, 9 of 38 patients (24%) patients had high tumor burden with >60% bone marrow plasma (BMPC) cells, 13 of 38 patients (34%) patients had extramedullary disease (EMD), and 11 of 38 (29%) patients had high-risk cytogenetics (Del 17p, t(14;16), t(4;14)) at baseline. At baseline, 24 of 38 (63%) had at least one high risk clinical feature, defined as presence of EMD, BMPC >60% or B2M >5.5. All 38 patients had at least three prior lines of therapy.

The interim CART-ddBCMA Phase 1 clinical results (June 2, 2023 cutoff date) demonstrate deep and durable responses in patients with poor prognostic factors.


All Patients:

Of the 38 evaluable patients with a median follow-up of 22 months

 

   

100% overall response rate (ORR) achieved in all patients per IMWG criteria

 

   

29 of 38 evaluable patients achieved a complete response (CR) or a stringent complete response (sCR) (> CR rate, 76%)

 

   

35 patients achieved a very good partial response or higher (>VGPR rate, 92%)

Median duration of response, progression free survival (PFS), and overall survival were not reached at the time of the June 2, 2023 data cut because 25 of 38 (66%) evaluable patients had ongoing responses.

The Kaplan-Meier method estimated PFS rates for 6, 12, and 18 months were 92%, 74%, and 67% respectively. Durable responses were also observed in patients with high-risk features (EMD, BMPC ≥ 60%, or B2M ≥ 5.5 mg/L at baseline) and high-risk cytogenetics.

PFS rates at 6-, 12-, and 18 months by Kaplan-Meier method were:

 

     PFS Rates (%)  
     6-month      12-month      18-month  

All dosed (n=38)

     92.1        74.3        67.5  

Age ≥65 years (n=20)

     95.0        84.4        78.4  

Complete responders (n=29)

     96.4        88.8        84.6  

High Risk Features* (n=24)

     91.7        73.3        68.1  

Extramedullary Disease (n=13)

     92.3        64.6        64.6  

High Risk Cytogenetics (n=11)

     81.8        70.1        70.1  

 

*

High risk features defined as presence of EMD, BMPC ≥ 60, or B2M ≥5.5 mg/L. Note: increased from prior presentation from 22 to 24 subjects as a result of database update based on monitoring and query resolution.

CART-ddBCMA dosed at RP2D (115 million (+/- 10) CAR+ T cells) continues to be well-tolerated at the time of the data cut:

 

   

Adverse events with CART-ddBCMA, including CRS and ICANS, were manageable

 

   

No tissue-targeted toxicities were observed

 

   

No cases of delayed neurotoxicity events or parkinsonian symptoms were observed

ASH Presentation Details:

Title: Phase 1 Study of CART-ddBCMA for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Results from at Least 1-Year Follow-up in All Patients

Speaker: Matthew J. Frigault, M.D., Clinical Director of the Cellular Therapy Service at Massachusetts General Cancer Center, and Assistant Professor at Harvard Medical School

Session Name: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR-T Cell Therapies for Multiple Myeloma and B Cell Lymphomas

Session Date: Monday, December 11, 2023

Session Time: 4:30 - 6:00 p.m. PT (CART-ddBCMA oral presentation will be at 5 p.m. PT)

Location: San Diego Convention Center, Room 6A, San Diego, California

Publication Number: 1023


Webcast Event:

Arcellx will host a live webcast event with an expert panel of clinicians to discuss the clinical results on Monday, December 11, 2023 at 8 p.m. PT. The event will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.

About Multiple Myeloma

Multiple Myeloma (MM) is a type of hematological cancer in which diseased plasma cells proliferate and accumulate in the bone marrow, crowding out healthy blood cells and causing bone lesions, loss of bone density, and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment, called a myeloma protein (M protein), causing kidney damage and impairing the patient’s immune function. Multiple myeloma is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all hematological cancer cases and 20% of deaths due to hematological malignancies. The median age of patients at diagnosis is 69 years with one-third of patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple co-morbidities and toxicities that can quickly escalate and become life-endangering.

About CART-ddBCMA

CART-ddBCMA is Arcellx’s BCMA-specific CAR-modified T-cell therapy utilizing the company’s novel BCMA-targeting binding domain for the treatment of patients with relapsed or refractory multiple myeloma. CART-ddBCMA is currently in a Phase 2 study. Arcellx’s proprietary binding domains are novel synthetic proteins designed to bind specific therapeutic targets. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy Designations by the U.S. Food and Drug Administration.

About Arcellx, Inc.

Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (rrMM) in a Phase 2 pivotal trial. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration.

Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, through two clinical-stage programs: a Phase 1 study of ACLX-001 for rrMM, initiated in the second quarter of 2022; and ACLX-002 in relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, initiated in the fourth quarter of 2022. For more information on Arcellx, please visit www.arcellx.com. Follow Arcellx on X (formerly known as Twitter) (@arcellx) and LinkedIn.


About Arcellx and Kite Pharma Collaboration

Arcellx and Kite, a Gilead Company, formed a global strategic collaboration to co-develop and co-commercialize Arcellx’s CART-ddBCMA candidate for the treatment of patients with relapsed or refractory multiple myeloma currently in a pivotal Phase 2 study. Kite and Arcellx will jointly advance and commercialize the CART-ddBCMA asset in the United States, and Kite will commercialize the product outside the U.S.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements in this press release that are not purely historical are forward-looking statements, including Arcellx’s plans for the clinical development of its product candidates, including anticipated announcements of additional data; Arcellx and Kite’s plans to advance and commercialize CART-ddBCMA; and the potential impact of Arcellx’s product candidates and platforms on patients and cell therapy. The forward-looking statements contained herein are based upon Arcellx’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including risks that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed with the Securities and Exchange Commission (SEC) on August 14, 2023 and the other documents that Arcellx may file from time to time with the SEC. These forward-looking statements are made as of the date of this press release, and Arcellx assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Investor Contact:

Myesha Lacy

Arcellx, Inc.

ir@arcellx.com

510-418-2412

Media Contact

Andrea Cohen

Sam Brown Inc.

andreacohen@sambrown.com

917-209-7163

###

EX-101.SCH 3 aclx-20231102.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 aclx-20231102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 aclx-20231102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g572316g1102072409981.jpg GRAPHIC begin 644 g572316g1102072409981.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 02, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001786205
Document Type 8-K
Document Period End Date Nov. 02, 2023
Entity Registrant Name Arcellx, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-41259
Entity Tax Identification Number 47-2855917
Entity Address, Address Line One 25 West Watkins Mill Road
Entity Address, Address Line Two Suite A
Entity Address, City or Town Gaithersburg
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20878
City Area Code 240
Local Phone Number 327-0603
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ACLX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
XML 8 d572316d8k_htm.xml IDEA: XBRL DOCUMENT 0001786205 2023-11-02 2023-11-02 false 0001786205 8-K 2023-11-02 Arcellx, Inc. DE 001-41259 47-2855917 25 West Watkins Mill Road Suite A Gaithersburg MD 20878 240 327-0603 false false false false Common Stock, $0.001 par value per share ACLX NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *Y)8E<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "N26)77C]CL.T K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)OIVE!(71S6?&D(+B@> O)[&ZP:4(RTN[;F\;=+J(/(.22F3_? M? /I=1#:1WR./F DB^EF=L.8A X;=B0* B#I(SJ5ZIP8D/ M=4!HF^86')(RBA0LP"JL1"9[HX6.J,C',][H%1\^XU!@1@,.Z'"D!+SFP.0R M,9SFH8^"VA68JG^B2T=8.?DG.R:FJ:IGKJ2RSMP>'MZ?"GK5G9, MI$:-^56R@DX!-^PR^;7;WN\>F&R;MJLXKYIVQSN13WOWOKC^\+L*.V_LWOYC MXXN@[.'7OY!?4$L#!!0 ( *Y)8E>97)PC$ 8 )PG 3 >&PO=&AE M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X? MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@ MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?+&A T%116F]?(+3E'S/X%/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1 MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?= MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%, M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;SC MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_ M+GW/I>^Y]#VATK\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE" M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT ML@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3 M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.' M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\ M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^ M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?! M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83 M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL' M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5 MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$% @ MKDEB5R@P8F=[! QQ$ !@ !X;"]W;W)K9D^2XL=MTVNF%#++1!!"5A.W\^Z[ M ?<4+[ZQP:#7CW97[PI&.ZG>=<2Y(?LD3O78B8S);EQ7!Q%/F.[(C*=P92U5 MP@RR]W8 M\9W/'U[%)C+V!WWM&\'%'?\ M+OA.'QT3.Y65E._VY#$<.YXEXC$/C)5@\+7E,Q['5@DX_CF(.M5_VH''QY_J M#\7D83(KIOE,QF\B--'8&3HDY&N6Q^95[G[AAPGUK%X@8UU\DEUY;]=S2)!K M(Y/#8"!(1%I^L_TA$,<#_!,#Z&$ +;C+/RHH[YAADY&2.Z+LW:!F#XJI%J,! M3J0V*PNCX*J <69R)X,<@FP(2T-RGQIA/LAC6F8;HC9R#?R)O=4-#H*WI2 ] M(?@BMQWBT0M"/7KUW^$NL%6 M *DA=[5";V9W')%_IJNM%&0PK^;B$J%;K." MK>L;G;& CQTH7,W5ECN3GW[P^][/"-]5Q7>%J4^F$+VPB.!#S#9-=/CX-8LU M1SBZ%4<7U3GD;@8DBL60PY#OR5?^T42$*WF>YP^&?>KU$*Q>A=5#Q:KZ6GYD MO(D%'SZ\_(I ]"N(_GD0$E@MC3RX4E'=17FWU?>@8AN>>/:D#=FWD6JR;.(8_(J68@!U\[OH\:- R]WLA$8EUSD @IXBN'5QN_C MSOT]WLR>2466;2ZU@:;UI\A.FDJ+(O6&@R'&5O<*'[?X(HU3V.&>1L$% M:-?#0.K&X..._B0#B,D\DBGF<2TB5W1PZ?4]K%/Y=4OP<>M^4\(8GD)@DB1/ M#_ZF&ZEPH;9-CU_W 1\W\86,12",2#?D&Y MLHO/IRNR%"9N7'PM(G:&Q49%!N\7Y$>O UV>9$R1+8MS3C*8J8Z80HGK#D!Q MRUXJ%MK*6WPD*]E8=RT"T]G3'QA)[?44]^4J=O?[(&+IAI_<1;8(O4P7=]-? M,:;:Y.E9)G^?<+6Q4?H""B:R-9BQM/&YI$70J!S-6VWQ%'?H3[(]@0RF6A3; MM/+9H!$+5SNY MRCQW+[BN.9V4!H$O,U"'F= 4Q7E6\-RA,CL^))?24-//<7 MAQ%GL#KM#7!]+:7Y/+$/_]6[F\F_4$L#!!0 ( *Y)8E>?H!OPL0( .(, M - >&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( *Y) M8E>7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports aclx-20231102.xsd aclx-20231102_lab.xml aclx-20231102_pre.xml d572316d8k.htm http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d572316d8k.htm": { "nsprefix": "aclx", "nsuri": "http://arcellx.com/20231102", "dts": { "schema": { "local": [ "aclx-20231102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] }, "labelLink": { "local": [ "aclx-20231102_lab.xml" ] }, "presentationLink": { "local": [ "aclx-20231102_pre.xml" ] }, "inline": { "local": [ "d572316d8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2023-11-02_to_2023-11-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d572316d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2023-11-02_to_2023-11-02", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d572316d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://arcellx.com//20231102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001193125-23-268942-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-268942-xbrl.zip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end